Embecta Corp. Form 10-Q Summary
Business context and period. Embecta is a global diabetes-care medical device company selling pen needles, syringes and related products. The report covers the quarter and six months ended March 31, 2023; amounts are in millions except per-share data. Embecta became a standalone public company on April 1, 2022, so the prior-year comparison includes periods when the business operated within BD and may not be fully comparable to standalone results.
Financial results
| Metric | Three months ended March 31, 2023 | Year-over-year change | Six months ended March 31, 2023 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $277.1 | +0.9% | $552.8 | -2.0% |
| Gross profit / margin | $189.8 / 68.5% | $191.2 / 69.7% prior year | $378.6 / 68.5% | $395.1 / 70.1% prior year |
| Operating income | $55.6 | -43.8% | $144.4 | -33.0% |
| Net income | $14.0 | -82.4% | $49.2 | -72.4% |
| Diluted EPS | $0.24 | Prior year $1.38 | $0.85 | Prior year $3.09 |
| Operating cash flow | Not separately presented | — | $47.4 | Prior year $321.4 |
Quarterly U.S. revenue was $146.4, up from $141.3; international revenue was $130.7, down from $133.2. For the six-month period, U.S. revenue was $295.7 versus $292.2, while international revenue was $257.1 versus $271.6.
Cash, liquidity and debt: Cash and cash equivalents were $346.4 at March 31, 2023, compared with $330.9 at September 30, 2022. Current assets were $756.3 and current liabilities $357.7. Principal debt outstanding was $1,640.5; long-term debt carrying value was $1,596.0, with $9.5 of current debt obligations. The $500.0 revolving facility was undrawn, and the company reported compliance with debt covenants. Weighted-average debt cost was 6.7%. A 100-basis-point change in rates would affect annualized Term Loan interest expense by approximately $9.4.
Six-month investing cash use was $10.5, primarily capital expenditures; financing cash use was $26.8, including $17.2 of dividends and $4.8 of debt repayments. Management said cash, operating cash flow and revolving borrowing capacity should provide sufficient flexibility for foreseeable requirements.
Material changes and unusual items
- Revenue increased modestly in the quarter, supported by $11.0 of favorable price and volume effects and contract manufacturing revenue, partly offset by $8.4 of adverse foreign exchange. Six-month revenue declined mainly because of a $24.0 unfavorable currency impact, partly offset by $13.0 of favorable price and volume effects and contract manufacturing revenue.
- Gross margin declined as product costs rose faster than revenue. Management cited inflation in raw materials, freight, direct labor and overhead.
- Selling and administrative expense increased 27.4% for the quarter and 22.4% for the six months, primarily reflecting added headcount and costs of operating as a standalone company. Separation and stand-up costs were $26.9 for the quarter and $37.2 for the six months, versus $7.4 and $15.8, respectively, a year earlier.
- Interest expense was $26.8 for the quarter and $52.4 for the six months, reflecting debt outstanding for a longer period and higher rates on variable-rate debt. Other expense included amounts payable to BD for taxes in deferred-close jurisdictions.
- The effective tax rate rose to 42.9% for the quarter and 39.0% for the six months, from 15.2% in both prior-year periods. The filing attributes the increase mainly to a valuation allowance on interest carryforwards and higher taxes on foreign earnings.
- Operating cash flow fell substantially year over year, with the comparison affected by prior-period receivables collections and current-period working-capital investment. Current-period inventory increased by $30.7, and amounts due from BD and prepaid expenses also used cash.
- In March 2023, Embecta entered a collaboration to develop and commercialize an interoperable automated glycemic controller for its insulin patch pump in development. It expensed an upfront $2.5 project payment; future commercial royalties would depend on sales.
Outlook, risks and contingencies
The filing provides no quantified financial guidance. Management said it expects higher benchmark rates, if they continue, to increase interest expense on variable-rate debt during the remainder of fiscal 2023. It also cited continued inflation and supply-chain cost pressures, while noting that inventory building and other measures had so far supported uninterrupted customer supply.
Key risks include competitive and pricing pressure, product commoditization, changing diabetes treatment patterns, foreign-exchange movements, inflation and supply disruption, and the costs and complexity of establishing standalone systems and controls. The company also depends on BD under transition and other separation agreements; deferred asset and liability transfers remained outstanding in certain jurisdictions. Three customers each accounted for at least 10% of gross revenue and together represented 39.6% of quarterly and 40.0% of six-month revenue. The company reported no material legal proceedings. Management concluded disclosure controls were effective; certain processes and internal controls continued to rely on BD during the transition-services period.
Important facts for investors to verify
- Whether standalone operating costs and separation expenses decline as the transition progresses, and whether ERP implementation remains on schedule and within expected costs.
- Whether pricing and volume gains can offset inflation, foreign-exchange headwinds and international revenue softness.
- Cash conversion and working-capital trends, particularly inventory levels and the collection and settlement of amounts due from BD.
- Debt-service capacity and covenant headroom under variable interest rates, alongside dividend commitments.
- Progress on deferred jurisdiction transfers, BD transition arrangements, and development of the patch-pump and controller collaboration.
- Customer concentration and the durability of sales to major customers.